AustCancer in gene test partnership
14 November, 2003 by Melissa TrudingerAustralian Cancer Technology (ASX:ACU) has partnered with Prof Ursula Kees at the Telethon Institute for Child Health Research to develop a diagnostic test able to rapidly screen tumour samples for deleted tumour suppressor genes.
Local researchers abuzz for bee genome publication
13 November, 2003 by Melissa TrudingerWith the honeybee genome about to be completed, work is ramping up in Assoc Prof Ben Oldroyd's laboratory at the University of Sydney to take advantage of the information it offers.
Bayer off the hook in NSW canola trial
12 November, 2003 by Graeme O'NeillNSW Agriculture Minister Ian MacDonald has advised Bayer CropScience that it will not have to destroy a trial crop of genetically modified herbicide-tolerant canola near Wagga, despite the discovery of a small number of canola plants in the surrounding buffer zone.
Premier in hunt for commercial partner
12 November, 2003 by Melissa TrudingerPremier Bionics (ASX:PBI) is ramping up its efforts to find a commercial partner for its Airway Clear sleep apnoea monitoring device.
Epitan: FDA intrigued by tanning drug
12 November, 2003 by Melissa TrudingerEpitan (ASX:EPT) has returned from its pre-IND meeting with the US Food and Drug Administration with a clear idea of what will be required to get approval for US clinical trials, according to CEO Wayne Millen.
Biotech veteran calls for tax breaks
12 November, 2003 by Melissa TrudingerLong time biotechnology investor Leon Serry has called on the federal government to implement a 100 per cent tax deduction as an incentive for significant institutional investment into Australian companies running Phase III clinical trials.
Analysts surprised by Pharmaxis' early drop
11 November, 2003 by Melissa TrudingerSydney-based pharmaceutical company Pharmaxis (ASX:PXS) listed on the ASX on Monday after successfully raising AUD$25 million in its IPO last month.
Arthron arthritis candidate a stayer
11 November, 2003 by Graeme O'NeillMelbourne biotechnology company Prima Biomed (ASX:PRR) is chuffed with an intriguing result reported by its subsidiary Arthron from trials of its experimental rheumatoid arthritis drugs in mice.
Spooner replaced as Ventracor CEO
11 November, 2003 by Melissa TrudingerFormer Sirtex Medical CEO Dr Colin Sutton has today taken over as chief of artificial heart company Ventracor (ASX:VCR), replacing Michael Spooner.
Alchemia launches $21m IPO
10 November, 2003 by Melissa TrudingerBrisbane-based carbohydrates company Alchemia is the latest company to seek listing on the ASX, announcing a AUD$21 million IPO to take place before Christmas.
Vision Bio takes aim at US market
07 November, 2003 by Melissa TrudingerMelbourne-based research instrument developer Vision BioSystems is gearing up to launch its Bond-X immunohistochemistry system in the US before the end of the year.
Heart monitor firm USCOM launches $16m IPO
07 November, 2003 by Melissa TrudingerDevices company USCOM is seeking to raise AUD$16 million in an IPO to raise funds to commercialise its heart monitor.
Cochlear hooks up with continence control company
07 November, 2003 by Melissa TrudingerA University of Melbourne spin-off and pioneering bionic ear company Cochlear have joined forces to develop a treatment for severe incontinence.
Biota hot on the trail of cold cure
07 November, 2003 by Graeme O'NeillMelbourne drug design company Biota Holdings is preparing to sign up a partner to develop its new lead compound to quell the so-called 'common' cold.
Metabolic launches Phase IIb trial
06 November, 2003 by Iain ScottMelbourne-based Metabolic Pharmaceuticals (ASX:MBP) has commenced what it says is the largest clinical trial ever undertaken by an Australian biotech, a Phase IIb trial of its obesity drug, AOD9604.
